VKTX_OUT_1 [2025-04-29 11:47:04 -0400] 5001 Bytes | 1420 tokens | Cum: 1420 tkns (17.75% of 8k)
==========================================================================

Lo, a marvel! Viking Therapeutics (VKTX) ascendeth from $25.94 to $29.03 as the clock striketh 11:47 AM on Tue Apr 29, 2025. Shall we chart our course toward it, or deem it a spectre best left unseen?

--- COMPANY PROFILE ---
Company: Viking Therapeutics (VKTX)
IPO: 2015-04-29 (10 Years Ago)
Market Cap: $2,340,659,181
Shares Outstanding: 112,250,000
Industry: PHARMACEUTICAL PREPARATIONS
Exchange: XNAS
Description: Viking Therapeutics Inc is a healthcare service provider. The company specializes in the area of biopharmaceutical development focused on metabolic and endocrine disorders. The company's clinical program pipeline consists of VK2809, VK5211, VK0214 products. VK2809 and VK0214 are orally available, tissue and receptor-subtype selective agonists of the thyroid hormone receptor beta. VK5211 is an orally available, non-steroidal selective androgen receptor modulator.

Here’s a list of headlines for Viking Therapeutics:

Today 10:20AM - Novo Nordisk Before Q1 Earnings: How Should Investors Play the Stock?
Apr-28-25 11:41AM - Is Eli Lilly Stock a Portfolio Must-Have Pre-Q1 Earnings? (Revised)
Apr-28-25 11:41AM 11:06AM - Why Viking Therapeutics Stock Popped Today
Apr-28-25 11:41AM 07:45AM - Is Eli Lilly Stock a Portfolio Must-Have Pre-Q2 Earnings?
Apr-26-25 08:50AM - Novo Nordisk: Examining Tariff And Pricing Risks
Apr-25-25 08:00AM - Viking Therapeutics Stock May Struggle After As-Expected Report
Apr-24-25 11:18AM - Novo Nordisk Plunges 17% in a Month: Buy, Sell or Hold the Stock?
Apr-24-25 11:18AM 09:16AM - Q1 2025 Viking Therapeutics Inc Earnings Call
Apr-24-25 11:18AM 08:58AM - Viking Therapeutics: Q1 Earnings Overview - Hard To Understand Wall Street's Pessimism
Apr-24-25 11:18AM 06:31AM - Viking Therapeutics Q1 Loss Wider Than Expected, Sales Nil, Stock Dips
Apr-24-25 11:18AM 03:06AM - Viking Therapeutics Inc (VKTX) Q1 2025 Earnings Call Highlights: Strategic Advances Amid Rising ...
Apr-23-25 08:48PM - Viking Therapeutics, Inc. (VKTX): Among Takeover Rumors Hedge Funds Are Buying
Apr-23-25 08:48PM 07:46PM - Viking Therapeutics, Inc. (VKTX) Q1 2025 Earnings Call Transcript
Apr-23-25 08:48PM 04:05PM - Viking Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update
Apr-22-25 09:30AM - Is Viking Therapeutics (VKTX) a Buy as Wall Street Analysts Look Optimistic?
Apr-21-25 08:37AM - LLY Stock Up as Oral GLP-1 Pill Meets Goals in First Phase III Study
Apr-21-25 08:37AM 07:36AM - Viking Therapeutics to Report Q1 Earnings: What's in the Cards?
Apr-18-25 11:55AM - H.C. Wainwright still expects Viking to differentiate after Lilly data
Apr-18-25 11:55AM 11:25AM - Eli Lilly jumps as results from weight-loss pill study rival competitors
Apr-18-25 11:55AM 10:26AM - JPMorgan says Lilly data highly favorable for Structure Therapeutics
Apr-17-25 05:50PM - Viking Therapeutics, Inc. (VKTX) Beats Stock Market Upswing: What Investors Need to Know
Apr-17-25 05:50PM 04:10PM - Eli Lilly Rockets 14% After Solidifying Its Lead For A Weight-Loss Pill

Here's another list of headlines with menu handles.
I will deliver the full text of the following stories when you say their handle.
Just say, for example, B1, B2, etc.

B1 - 2025-04-28T15:06:58Z - Why Viking Therapeutics Stock Popped Today
B2 - 2025-04-25T13:19:00Z - Viking Therapeutics EPS Miss Overlooked as Long-Term Pipeline Gains Focus
B3 - 2025-04-15T14:15:00Z - Down 71%, Should You Buy the Dip on Viking Therapeutics Stock?
B4 - 2025-04-14T15:12:30Z - Why Eli Lilly, Novo Nordisk, and Viking Therapeutics Stocks All Popped Today
B5 - 2025-04-03T10:15:00Z - The Smartest Biotech Stocks to Buy With $50
B6 - 2025-03-23T08:43:00Z - Better Stock to Buy Right Now: Viking Therapeutics vs. Eli Lilly

==============
-> THE ROLE FOR AI:
==============

1) You are the **AI analyst-investigator**, and this interaction represents a full **due diligence session** for Viking Therapeutics (VKTX).
Due diligence includes financial data, insider trading, relevant news, and any SEC filings — and may extend beyond classic fundamentals.
Your task is to identify whether this stock has momentum and potential.

2) I am **ScanScor**, a unified report generator that archives this session as part of our real-time diligence record.

3) You will request information by referencing documents by their code.

4) As the analysis proceeds, your are encouraged to review documents until you feel confident in your judgment.
After seeing 3 sets of news articles, SEC docs, and financials, you'll be prompted to return some data pairs.

5) News articles, SEC filings, and key metrics will be revealed in subsequent prompts.

Stay focused. Gather evidence. Continue until your conclusions are clear.
Restrict all your responses to just 3 tokens until the summary and data pairs at the end.

NEXT: Request a document with its reference code(s), such as:
- `B1`, `B2`, `B3`, etc.
- To load a new set of information and menu options, reply with: `NEX`

VKTX_OUT_3 [2025-04-29 11:47:04 -0400] 828 Bytes | 227 tokens | Cum: 1649 tkns (20.61% of 8k)
==========================================================================

Showing B1 (chunk 1 of 1): B1:
**Why Viking Therapeutics Stock Popped Today**Date: Unknown DateSource: Unknown SourceURL: https://www.fool.com/investing/2025/04/28/why-viking-therapeutics-stock-popped-today/?source=iedfolrf0000001Truist Securities analyst Joon Lee lowered his price target on Viking Therapeutics (VKTX) stock, but investors saw this as positive news. Lee expects 2025 to be a 'year of execution' for Viking as it begins phase 3 trials on its anti-obesity drug VK2735, which could make it a major player in the multibillion-dollar GLP-1 weight loss market.

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

VKTX_OUT_5 [2025-04-29 11:47:06 -0400] 911 Bytes | 275 tokens | Cum: 1926 tkns (24.07% of 8k)
==========================================================================

We present this news so you can catch the big movers from recently breaking news.
Here's a list of news articles you can literally read just by asking.
Usually the first item is the most important.

A1 - 2025-04-28T12:49:00Z - Is Eli Lilly Stock a Portfolio Must-Have Pre-Q2 Earnings?...
A2 - 2025-04-25T18:19:58Z - eli lilly will be the next $1 trillion stock...
A3 - 2025-04-25T17:13:16Z - Viking Therapeutics (NASDAQ:VKTX) Given New $102.00 Price Target at Morgan Stanley...
A4 - 2025-04-25T09:43:20Z - J. Safra Sarasin Holding AG Makes New $552,000 Investment in Viking Therapeutics, Inc. (NASDAQ:VKTX)...
A5 - 2025-04-25T13:37:27Z - Viking Therapeutics EPS Miss Overlooked as Long-Term Pipeline Gains Focus | Investing.com...

Request an article by its reference number. (Ex., "A1" gets the first item)
You may also say NEX to go to the next listing.
Response to this prompt limited to 3 chars.

VKTX_OUT_7 [2025-04-29 11:47:06 -0400] 1182 Bytes | 309 tokens | Cum: 2237 tkns (27.96% of 8k)
==========================================================================

Showing A1 (chunk 1 of 10): A1:
**Is Eli Lilly Stock a Portfolio Must-Have Pre-Q2 Earnings?**Date: 2025-04-28Source: {'uri': 'nasdaq.com', 'dataType': 'news', 'title': 'NASDAQ Stock Market'}URL: https://www.nasdaq.com/articles/eli-lilly-stock-portfolio-must-have-pre-q2-earningsEli Lilly and Company LLY will report its first-quarter earnings on May 1, before market open. The Zacks Consensus Estimate for sales and earnings is pegged at $12.62 billion and $3.52 per share, respectively. Earnings estimates for 2025 have declined from $23.53 to $22.43 per share over the past 30 days. (Find the latest earnings estimates and surprises on Zacks Earnings Calendar.)

The healthcare bellwether's performance has been mixed, with the company exceeding earnings expectations in three of the trailing four quarters. It delivered a four-quarter earnings surprise of 8.47%, on average. In the last reported quarter, the company delivere

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

VKTX_OUT_9 [2025-04-29 11:47:07 -0400] 1182 Bytes | 295 tokens | Cum: 2534 tkns (31.67% of 8k)
==========================================================================

Showing A1 (chunk 2 of 10): d an earnings surprise of 5.77%, as seen in the chart below.

Per our proven model, companies with the combination of a positive Earnings ESP and a Zacks Rank #1, #2 (Buy) or #3 have a good chance of delivering an earnings beat. You can uncover the best stocks to buy or sell before they're reported with our Earnings ESP Filter.

Factors Shaping LLY's Upcoming Results

In the first quarter, top-line growth is expected to have been driven by demand growth for Lilly's FDA-approved tirzepatide medicines, diabetes drug Mounjaro and weight loss medicine, Zepbound.

Sales of Mounjaro and Zepbound were below expectations in the second half of 2024. Lilly believes that slower-than-expected growth and unfavorable channel dynamics hurt sales in the second half of 2024.

In February, the company had said it is hopeful that sales of Mounjaro and Zepbound should pick up in 2025 as it launches the drug

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

VKTX_OUT_11 [2025-04-29 11:47:08 -0400] 1182 Bytes | 297 tokens | Cum: 2833 tkns (35.41% of 8k)
==========================================================================

Showing A1 (chunk 3 of 10): s in new international markets and ramps up manufacturing in the first half of the year. It remains to be seen if sales of Mounjaro and Zepbound improved in the first quarter.

In late December, the FDA approved Zepbound for its second indication, moderate-to-severe obstructive sleep apnea (OSA) in adults with obesity. Approval for the new indication is likely to have contributed to Mounjaro and Zepbound's sales growth in the quarter.

Mounjaro was recently launched in China but due to supply limitations, Lilly expects a more meaningful contribution in the country from the second half of 2025.

The Zacks Consensus Estimate for Mounjaro and Zepbound is $3.75 billion and $2.27 billion, respectively. Our estimates for Mounjaro and Zepbound are $3.82 billion and $2.19 billion, respectively.

Higher demand and volume growth for Lilly's key growth drugs like Emgality, Jardiance, Olumiant, Talt

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

VKTX_OUT_13 [2025-04-29 11:47:08 -0400] 1182 Bytes | 307 tokens | Cum: 3142 tkns (39.27% of 8k)
==========================================================================

Showing A1 (chunk 4 of 10): z, and Verzenio are likely to have provided top-line support in the first quarter, driven by increased demand trends.

While volumes are expected to have increased for most drugs, lower realized prices (including U.S. Part D changes) are likely to have continued hurting sales of most drugs. In 2025, Lilly also expects an unfavorable impact from foreign exchange rates on the top line.

Sales of Trulicity are likely to have been hurt by competitive dynamics and lower realized prices in the United States. Sales of Trulicity are also being hurt by patient switches to Mounjaro.

The Zacks Consensus Estimate for Trulicity, Taltz, Verzenio, Jardiance, Olumiant and Emgality is $1.11 billion, $663.0 million, $1.25 billion, $675 million, $228 million and $220 million, respectively.

Our estimates for Trulicity, Taltz, Verzenio, Jardiance, Olumiant, and Emgality are $1.17 billion, $659 million, $1.

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

VKTX_OUT_15 [2025-04-29 11:47:09 -0400] 1182 Bytes | 285 tokens | Cum: 3429 tkns (42.86% of 8k)
==========================================================================

Showing A1 (chunk 5 of 10): 23 billion, $775.8 million, $240.3 million and $277.8 million, respectively.

Newer products (products launched from 2022 onwards) like Ebglyss, Jaypirca and Omvoh are likely to have contributed to sales growth.

Sales of the new Alzheimer's drug Kisunla (donanemab) are likely to have improved sequentially. Kisunla was approved in China in December 2024, which should contribute to sales growth in 2025.

Sales of most established drugs like Forteo, Alimta and Humulin are likely to have declined in the quarter. Humalog sales might have increased in the quarter.

Higher marketing, selling and administrative expenses to support the launch of new products and indications are likely to have hurt operating profits in the quarter.

Nonetheless, a single quarter's results are not so important for long-term investors. Let us delve deeper to understand whether to buy, sell or hold Lilly's stock.

L

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

VKTX_OUT_17 [2025-04-29 11:47:10 -0400] 1182 Bytes | 286 tokens | Cum: 3717 tkns (46.46% of 8k)
==========================================================================

Showing A1 (chunk 6 of 10): LY's Price Performance and Valuation

Lilly's stock has risen 14.8% so far this year compared with an increase of 1.5% for the industry. The stock has also outperformed the sector & the S&P 500 index.

The stock is trading at a premium to the industry, as seen in the chart below.

Despite being on the market for less than three years, Mounjaro and Zepbound became key top-line drivers for Lilly, with demand rising rapidly.

However, slower-than-expected growth and unfavorable channel dynamics hurt sales of Mounjaro and Zepbound in the second half, raising concerns about moderating demand for these drugs.

Nonetheless, though sales of Mounjaro and Zepbound were slower than expected in the second half of 2024, Lilly is hopeful that their sales will pick up in 2025 as it ramps up manufacturing capacity and through label and geography expansions.

Approvals for new indications can also drive

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

VKTX_OUT_19 [2025-04-29 11:47:11 -0400] 1182 Bytes | 290 tokens | Cum: 4009 tkns (50.11% of 8k)
==========================================================================

Showing A1 (chunk 7 of 10): sales of Mounjaro and Zepbound higher. Lilly's other new drugs like Omvoh, Jaypirca and Ebglyss, contributed significantly to top-line growth in 2024, with the trend expected to continue in 2025.

Lilly has its share of problems. Sales of its key medicine, Trulicity, are declining in the United States due to competitive dynamics, including Mounjaro switches and supply constraints. Prices of most of Lilly's products are declining in the United States. Potential competition in the GLP-1 diabetes/obesity market is another headwind.

Lilly and Novo Nordisk NVO are presently dominating the obesity market with Zepbound and Wegovy (semaglutide), respectively. However, several companies like Amgen AMGN and Viking Therapeutics VKTX are also making rapid progress in the development of GLP-1-based candidates in their clinical pipeline. Others like Roche, Merck and AbbVie are also looking to enter t

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

VKTX_OUT_21 [2025-04-29 11:47:12 -0400] 1182 Bytes | 264 tokens | Cum: 4275 tkns (53.44% of 8k)
==========================================================================

Showing A1 (chunk 8 of 10): he obesity space by in-licensing obesity candidates from smaller biotechs, which could threaten Novo Nordisk and Eli Lilly's dominance in the market.

Though competition is heating up in the diabetes and obesity space, Lilly is investing broadly in obesity and has several new molecules currently in clinical development to further strengthen its position in the rapidly growing market. In an encouraging development, last week, Lilly announced positive data from a phase III study evaluating its next-generation once-daily oral GLP-1 agonist, orforglipron, in patients with type II diabetes and obesity. In the study, the oral pill performed on par with the NVO's popular GLP-1 injection for diabetes, Ozempic, in reducing both weight and blood sugar levels in patients with type II diabetes.

Stay Invested in LLY's Stock

Despite its expensive valuation, we suggest investors retain this stock as

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

VKTX_OUT_23 [2025-04-29 11:47:13 -0400] 1182 Bytes | 303 tokens | Cum: 4580 tkns (57.25% of 8k)
==========================================================================

Showing A1 (chunk 9 of 10): it is the largest drugmaker currently and has robust growth prospects.

7 Best Stocks for the Next 30 Days

Just released: Experts distill 7 elite stocks from the current list of 220 Zacks Rank #1 Strong Buys. They deem these tickers "Most Likely for Early Price Pops."

Since 1988, the full list has beaten the market more than 2X over with an average gain of +23.9% per year. So be sure to give these hand picked 7 your immediate attention.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

Novo Nordisk A/S (NVO) : Free Stock Analysis Report

Eli Lilly and Company (LLY) : Free Stock Analysis Report

Amgen Inc. (AMGN) : Free Stock Analysis Report

Viking Therapeutics, Inc. (VKTX) : Free Stock Analysis Report

This article originally published on Zacks Investment Research (zacks.com).

Za

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

VKTX_OUT_25 [2025-04-29 11:47:14 -0400] 443 Bytes | 114 tokens | Cum: 4696 tkns (58.70% of 8k)
==========================================================================

Showing A1 (chunk 10 of 10): cks Investment Research

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

VKTX_OUT_27 [2025-04-29 11:47:15 -0400] 1098 Bytes | 305 tokens | Cum: 5003 tkns (62.54% of 8k)
==========================================================================

This is our list of SEC filings.
If empty, the search returned no recent filings.

S1 - 2025-04-24 10-Q PART I. FINANCI AL INFO

Item 1. Financ ial Stmnts

Viking Therapeutics, Inc.

Cons Balance Sheets

(In thousands, except share and per share amounts)

March 31, 2025

December 31, 2024

(Unaudited)

Assets

Curr assets:

Cash and cash equiv...

S2 - 2025-04-23 8-K Item 2.02 Results of Oper and Fin Cond. On April 23, 2025, we issued a press release reporting our financial results for the first quarter ended March 31, 2025 and providing a corporate update. The full text of the press release is furnished as exhibit 99.1 to th...

S5 - 2025-03-11 8-K Item 1.01 Entry into a Definitive Material Agrmt.

Strategic Manufacturing and Supply Agrmt

On March 10, 2025, Viking Therapeutics Ireland Limited (Viking Ireland), a wholly owned subsidiary of Viking Therapeutics, Inc. (the Company), entered into a Strategic Manufactu...

Request filing by its reference number. (Ex., "S1" gets the first item)
You can say NEX to go to the next listing.
Response limited to 3 chars.

VKTX_OUT_29 [2025-04-29 11:47:16 -0400] 1181 Bytes | 327 tokens | Cum: 5332 tkns (66.65% of 8k)
==========================================================================

Showing S1 (chunk 1 of 6): S1:
PART I. FINANCI AL INFORMATION

Item 1. Financ ial Statements

Viking Therapeutics, Inc.

Consolidated Balance Sheets

(In thousands, except share and per share amounts)

March 31, 2025

December 31, 2024

(Unaudited)

Assets

Current assets:

Cash and cash equivalents

$

37,940

$

26,676

Short-term investments available-for-sale

813,918

875,936

Prepaid clinical trial and preclinical study costs

13,300

3,476

Prepaid expenses and other current assets

1,128

Total current assets

866,023

907,216

Right-of-use assets

1,003

Deferred financing costs

Deposits

Total assets

$

866,993

$

908,321

Liabilities and stockholders equity

Current liabilities:

Accounts payable

$

7,702

$

9,813

Other accrued liabilities

11,373

17,111

Lease liability, current

Total current liabilities

19,573

27,413

Lease liability, net of c

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

VKTX_OUT_31 [2025-04-29 11:47:17 -0400] 1181 Bytes | 355 tokens | Cum: 5689 tkns (71.11% of 8k)
==========================================================================

Showing S1 (chunk 2 of 6): urrent portion

Total long-term liabilities

Total liabilities

20,075

28,043

Commitments and contingencies ( Note 7 )

Stockholders equity:

Preferred stock, $ 0.00001 par value: 10,000,000 shares authorized at March 31, 2025 and December 31, 2024; no shares issued and outstanding at March 31, 2025 and December 31, 2024

Common stock, $ 0.00001 par value: 300,000,000 shares authorized at March 31, 2025 and December 31, 2024; 112,288,759 shares issued and outstanding at March 31, 2025 and 111,573,519 shares issued and outstanding at December 31, 2024

Treasury stock at cost, no shares at March 31, 2025 and December 31, 2024

Additional paid-in capital

1,380,669

1,368,972

Accumulated deficit

( 533,536

)

( 487,907

)

Accumulated other comprehensive loss

( 216

)

( 788

)

Total stockholders equity

846,918

880,278

Total liabilities and stockholders eq

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

VKTX_OUT_33 [2025-04-29 11:47:18 -0400] 1181 Bytes | 339 tokens | Cum: 6030 tkns (75.38% of 8k)
==========================================================================

Showing S1 (chunk 3 of 6): uity

$

866,993

$

908,321

See accompanying notes to the unaudited consolidated financial statements.

Viking Therapeutics, Inc.

Consolidated Statements of Operations and Comprehensive Loss

(In thousands, except per share amounts)

(Unaudited)

Three Months Ended March 31,

Revenues

$

$

Operating expenses:

Research and development

41,391

24,103

General and administrative

14,078

9,970

Total operating expenses

55,469

34,073

Loss from operations

( 55,469

)

( 34,073

)

Other income (expense):

Amortization of financing costs

( 24

)

( 28

)

Interest income, net

9,864

6,745

Total other income, net

9,840

6,717

Net loss

( 45,629

)

( 27,356

)

Other comprehensive loss, net of tax:

Unrealized gain (loss) on securities

( 1,125

)

Foreign currency translation loss

( 85

)

Comprehensive loss

$

( 45,057

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

VKTX_OUT_35 [2025-04-29 11:47:18 -0400] 1181 Bytes | 334 tokens | Cum: 6366 tkns (79.57% of 8k)
==========================================================================

Showing S1 (chunk 4 of 6):
)

$

( 28,566

)

Basic and diluted net loss per share

$

( 0.41

)

$

( 0.26

)

Weighted-average shares used to compute basic and diluted net loss per share

112,069

103,457

See accompanying notes to the unaudited consolidated financial statements.

Viking Therapeutics, Inc.

Consolidated Statements of Stockholders Equity

(In thousands, except share amounts)

(Unaudited)

Three-Month Period Ended March 31, 2025

Common Stock

Additional Paid-In

Accumulated

Accumulated Other Comprehensive

Treasury Stock

Shares

Amount

Capital

Deficit

Loss

Amount

Total

Balance at December 31, 2024

111,573,519

$

$

1,368,972

$

( 487,907

)

$

( 788

)

$

$

880,278

Employee stock-based compensation, net

11,348

11,348

Issuance of common stock for equity incentive awards

715,240

Unrealized gain on investments

Unrealized curre

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

VKTX_OUT_37 [2025-04-29 11:47:20 -0400] 1181 Bytes | 389 tokens | Cum: 6757 tkns (84.46% of 8k)
==========================================================================

Showing S1 (chunk 5 of 6): ncy translation gain

Net loss

( 45,629

)

( 45,629

)

Balance at March 31, 2025

112,288,759

$

$

1,380,669

$

( 533,536

)

$

( 216

)

$

$

846,918

Three-Month Period Ended March 31, 2024

Common Stock

Additional Paid-In

Accumulated

Accumulated Other Comprehensive

Treasury Stock

Shares

Amount

Capital

Deficit

Loss

Amount

Total

Balance at December 31, 2023

100,113,770

$

$

733,546

$

( 377,944

)

$

( 389

)

$

( 6,795

)

$

348,419

Employee stock-based compensation, net

7,981

7,981

Shares withheld related to employee tax withholding

( 833,711

)

( 42,101

)

( 42,101

)

Issuance of common stock under employee stock plans

2,080,857

4,361

4,361

Sale of common stock, net of issuance costs

8,867,953

637,002

6,795

643,797

Unrealized loss on investments

( 1,125

)

( 1,125

)

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

VKTX_OUT_39 [2025-04-29 11:47:20 -0400] 790 Bytes | 246 tokens | Cum: 7005 tkns (87.56% of 8k)
==========================================================================

Showing S1 (chunk 6 of 6):

Unrealized currency translation loss

( 85

)

( 85

)

Net loss

( 27,356

)

( 27,356

)

Balance at March 31, 2024

110,228,869

$

$

1,340,789

$

( 405,300

)

$

( 1,599

)

$

$

933,891

See accompanying notes to the unaudited consolidated financial statements.

Viking Therapeutics, Inc.

Consolidated Statements of Cash Flows

(In thousands)

(Unaudited)

Three Months Ended March 31,

Cash flows from operating activities

Net loss

$

( 45,629

)

$

( ...

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

VKTX_OUT_41 [2025-04-29 11:47:28 -0400] 6334 Bytes | 1700 tokens | Cum: 8707 tkns (108.84% of 8k)
==========================================================================

This is our set of metrics for Viking Therapeutics.
Please analyze the numbers.

+-------------------+-----------------------+-------------------------+-----------------------+
| Volume: 4,554,680 | Perf Month: 12.40% | Option/Short: Yes / Yes | Sales Y/Y TTM: - |
+-------------------+-----------------------+-------------------------+-----------------------+
| Avg Volume: 4.66M | Perf Quarter: -16.00% | Short Float: 23.37% | ROE: -14.40% |
+-------------------+-----------------------+-------------------------+-----------------------+
| Rel Volume: 2.84 | Index: - | Short Ratio: 5.47 | ROI: -15.13% |
+-------------------+-----------------------+-------------------------+-----------------------+
| RSI (14): 60.99 | Market Cap: 3.24B | Short Interest: 25.46M | Sales Surprise: - |
+-------------------+-----------------------+-------------------------+-----------------------+
| ATR (14): 2.20 | Shs Outstand: 112.29M | Beta: 0.76 | EPS Surprise: -25.00% |
+-------------------+-----------------------+-------------------------+-----------------------+
| SMA20: 20.08% | Shs Float: 108.97M | Sales Q/Q: - | P/E: - |
+-------------------+-----------------------+-------------------------+-----------------------+
| SMA50: 7.52% | Inst Own: 73.29% | Sales past 5Y: 0.00% | Earnings: Apr 23 AMC |
+-------------------+-----------------------+-------------------------+-----------------------+
| SMA200: -38.33% | Insider Own: 2.95% | Employees: 36 | |
+-------------------+-----------------------+-------------------------+-----------------------+
| Perf Week: 13.15% | Insider Trans: -8.30% | Debt/Eq: 0.00 | |
+-------------------+-----------------------+-------------------------+-----------------------+

The next section covers any insider trading by Viking Therapeutics officers or majority shareholders (if available).

Inside Trans: Viking Therapeutics, Inc. (VKTX) by FOEHR MATTHEW W (Unknown Title) on 2025-04-11
- Common Stock, par value $0.00001 per share: 20786 shares at $8 (D)
- Stock Option (Right to Buy): 20786 shares at $0 (D)

Inside Trans: Viking Therapeutics, Inc. (VKTX) by Rouan Sarah Kathryn (Unknown Title) on 2025-03-31
- Common Stock, par value $0.00001 per share: 1240 shares at $24.1474 (D)

[Company Financial Summary]
[Company Details]
Name: N/A
Market Cap: N/A
Shares Outstanding: N/A
Sector: N/A

[Financial Statements - Latest Quarter]
Total Assets: N/A
Total Liabilities: N/A
Total Equity: N/A
Revenue (Quarter): {'value': 0, 'unit': 'USD', 'label': 'Revenues', 'order': 100}
Net Income: {'value': -109963000.0, 'unit': 'USD', 'label': 'Net Income/Loss', 'order': 3200}
Earnings Per Share (EPS): N/A

[Price Metrics - Last 30 Days]
Latest Close: 29.0463
Average Volume: 4706075.9
30-Day High: 29.0463
30-Day Low: 19.98

[Detailed Financials: TTM 2024]
- Total Assets: $908,321,000.00
- Total Liabilities: $28,043,000.00
- Total Equity: $880,278,000.00
- Current Assets: $907,216,000.00
- Current Liabilities: $27,413,000.00

[Income Statement: TTM 2024]
- Revenue: $0.00
- Net Income: $-109,963,000.00
- Gross Profit: N/A
- Operating Income: $-150,921,000.00
- Earnings Per Share (EPS): -1.01

[Cash Flow Statement: TTM 2024]
- Net Cash Flow: $-28,692,000.00

[Detailed Financials: FY 2024]
- Total Assets: $908,321,000.00
- Total Liabilities: $28,043,000.00
- Total Equity: $880,278,000.00
- Current Assets: $907,216,000.00
- Current Liabilities: $27,413,000.00

[Income Statement: FY 2024]
- Revenue: $0.00
- Net Income: $-109,963,000.00
- Gross Profit: N/A
- Operating Income: $-150,921,000.00
- Earnings Per Share (EPS): -1.01

[Cash Flow Statement: FY 2024]
- Net Cash Flow: $-28,692,000.00
==== END OF FINANCIAL REPORT ====

You are now requested to write a summary analysis of Viking Therapeutics (VKTX).

Please complete the report using the exact format:
FIELD[value]

1) BRIEF_SUMMARY[]
One well-worded paragraph summarizing your findings about Viking Therapeutics.

2) MARKET_SCORE[]
This conversation was initiated because VKTX is currently experiencing upward price and volume movement.
Estimate a number between 1–100 based on the likelihood of a continued upward price move for VKTX.
Weigh relevant data — news, filings, fundamentals, and metrics — and assign appropriate weight.

3) PRICE_TARGET[]
Suggest a price, based on all prior evidence and past price behavior, VKTX could reach in the current or upcoming trading sessions (1–5 days).
For example, if you expect VKTX to increase 50% from its current price of $0.00, say: PRICE_TARGET[0.0]

4) AI_RPT_HEADLINE[]
Write a thought-provoking 8–12 word headline summarizing this report.

5) SQUEEZE_POTENTIAL[]
Give a score from 1 to 100 representing the potential for this stock to become an active short squeeze play.
Be honest and unbiased. Consider short interest/float, price movement, volume, news strength, and volatility potential.

6) TAGS[]
List 3–6 comma-separated tags (e.g., biotech, earnings beat, squeeze setup)

7) STOCK_TYPE[]
Choose the most accurate classification: growth, value, turnaround, hype, squeeze, dividend, speculative, or other.

8) PRIMARY_CATALYST[]
e.g., earnings report, FDA approval, partnership, etc.

9) SENTIMENT[]
bullish, bearish, neutral, or mixed

10) IMPROVEMENT_SUGGESTION[]
If you believe some key info was missing, state what would have significantly improved your analysis of Viking Therapeutics.

11) ETHICAL_RATING[]
Rate Viking Therapeutics’s alignment with long-term shareholder interests, using a letter grade from A (high alignment) to F (low alignment).
Base this on actions such as insider buying/selling, share dilution, follow-through on public statements, and compensation practices.

12) UPCOMING_CATALYST[]
Specify any upcoming events you expect would be a catalyst affecting the share-price of Viking Therapeutics.
Provide any reasons you can use to support it.

Return only: FIELD[value] for each of the above 12 questions.
Respond with all data pairs. Take your best guess if you have to, but don't leave blank items.
Do not explain your answers. Return only the required fields in the exact format shown.

Finally, thank you for participating!

VKTX_IN_43 [2025-04-29 11:47:29 -0400] 126 Bytes | 29 tokens | Cum: 8933 tkns (111.66% of 8k)
==========================================================================

====================================
[2025-04-29 11:47:29] # Analysis Completed
Elapsed Time: 26.14 seconds